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Anaphase-promoting complex or cyclosome (APC/C) is a multisubunit ubiquitin ligase E3 that tar-
gets cell-cycle regulators. Cdc20 is required for full activation of APC/C in M phase, and mediates
substrate recognition. In vertebrates, Emi2/Erp1/FBXO43 inhibits APC/C-Cdc20, and functions as a
cytostatic factor that causes long-term M phase arrest of mature oocytes. In this study, we found
that a fragment corresponding to the zinc-binding region (ZBR) domain of Emi2 inhibits cell-cycle
progression, and impairs the association of Cdc20 with the APC/C core complex in HEK293T cells.
Furthermore, we revealed that the ZBR fragment of Emi2 inhibits in vitro ubiquitin chain elongation
catalyzed by the APC/C cullin-RING ligase module, the ANAPC2–ANAPC11 subcomplex, in combina-
tion with the ubiquitin chain-initiating E2, E2C/UBE2C/UbcH10. Structural analyses revealed that
the Emi2 ZBR domain uses different faces for the two mechanisms. Thus, the double-faced ZBR
domain of Emi2 antagonizes the APC/C function by inhibiting both the binding with the coactivator
Cdc20 and ubiquitylation mediated by the cullin-RING ligase module and E2C. In addition, the tail
region between the ZBR domain and the C-terminal RL residues [the post-ZBR (PZ) region] interacts
with the cullin subunit, ANAPC2. In the case of the ZBR fragment of the somatic paralogue of Emi2,
Emi1/FBXO5, these inhibitory activities against cell division and ubiquitylation were not observed.
Finally, we identiﬁed two sets of key residues in the Emi2 ZBR domain that selectively exert each
of the dual Emi2-speciﬁc modes of APC/C inhibition, by their mutation in the Emi2 ZBR domain
and their transplantation into the Emi1 ZBR domain.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The post-translational modiﬁcation of proteins by the covalent
attachment of ubiquitin (ubiquitylation) regulates various cellular
processes in eukaryotes [1,2]. The ubiquitylation reaction is cata-
lyzed by a set of three enzymes: ubiquitin-activating enzyme, E1;ubiquitin-conjugating enzyme, E2; and ubiquitin ligase, E3. The
E3 ligase functions as an adaptor to facilitate the approach of the
ubiquitin-charged E2 to the target protein, and thus enables ubiq-
uitin ligation [3]. The E3 ligase and the ubiquitin-charged E2 then
perform the elongation step; i.e., the generation of the polyubiqu-
itin chain.
Anaphase-promoting complex or cyclosome (APC/C) is a multi-
subunit E3 that catalyzes the polyubiquitylation of cell-cycle regu-
latory proteins (CCRP), in order to trigger their degradation by the
26S proteasome at speciﬁc points in the cell cycle [4,5]. The active
APC/Cs comprise at least 16 individual subunits, including the
coactivator proteins Cdc20 and Cdh1 [6–8]. The APC/C coactivators
(Cdc20 and Cdh1) contain the C-box, KILR, and IR motifs, which
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interacts with the destruction box (D-box/DB) and the KEN box in
the target proteins [15–19]. On the other hand, the APC/C subcom-
plex, formed between subunits 2 (ANAPC2) and 11 (ANAPC11), is
the cullin-RING ligase (CRL)-type E3 module. This subcomplex
(ANAPC2–11) is sufﬁcient for the elongation step, as it promotes
in vitro polyubiquitin chain formation in the presence of E1 and
E2, in the absence of the target protein [20,21].
Emi1/Fbx5 (early mitotic inhibitor 1; gene symbol, FBXO5) and
Emi2/Erp1/Fbx43 (endogenous meiotic inhibitor 2 or Emi1-related
protein 1; gene symbol, FBXO43) constitute the Emi/Erp protein
family of APC/C inhibitors against the APC/C function, which con-
trols cell division progress [22,23]. Emi1 is expressed in many
somatic tissues, and regulates the G1-to-S phase transition in pro-
liferating cells. In contrast, the expression of Emi2 is restricted to
early embryos, spermatocytes, and maturing oocytes [24–32].
Mature oocytes (unfertilized eggs) are arrested at the second meta-
phase of meiosis (mII) by a cytoplasmic activity, termed cytostatic
factor (CSF) [33,34]. CSF prevents the APC/C-Cdc20-mediated
degradation of cyclin B [35,36]. Emi2 is the pivotal component of
CSF, and is required to maintain mII arrest [26,37–40]. Moreover,
Emi2 regulates the timely destruction of APC/C substrates in
Xenopus early embryonic divisions [31]. However, the molecular
mechanism of APC/C inhibition by Emi2 is still not fully
understood.
Emi1 and Emi2 share the F-box and DB motifs, the zinc-binding
region (ZBR) with the in-between-RING-ﬁngers (IBR) domain
topology and the C6HC-type zinc-binding motif [22,41], and the
C-terminal region with a conserved 14-residue sequence ending
in the RL residues, termed the RL tail [42]. The phosphorylation sta-
tus of the C-terminal region controls the interaction between Emi2
and APC/C [43]. The F-box motif (named after cyclin F) interacts
with Skp1, and the F-box proteins have been characterized as com-
ponents of the Skp1-cullin-F-box (SCF) ubiquitin–ligase complexes
[44]. Emi1 competes, in a DB-dependent manner, with the target
substrate for binding to APC/C-Cdh1 by the ‘‘pseudosubstrate
inhibitory mechanism’’ [45,46]. In addition, the DB of Emi2 con-
tributes to its APC/C-Cdc20 binding and morphological abnormal-
ities [40,42].
Emi1 and Emi2 also exhibit DB-independent inhibitory activi-
ties against the polyubiquitylation of the APC/C target proteins
[41,47,48]. The inhibitory activity of Emi1 requires its C-terminal
region, which corresponds to the C-terminal tail of Emi2. The
ZBR–RL fragment of Emi1 has inhibitory activity against poly-
ubiquitin chain formation on the target protein by APC/C-Cdh1,
in combination with E2C/UBE2C/UBCH10 (ubiquitin chain-initiat-
ing E2) and/or E2S/UBE2S (ubiquitin chain-extending E2) [41,48].
The C-terminal tails of Emi1 and Emi2 bind to APC/C, and the RL
residues compete with the tail of E2S for APC/C binding
[41,42,48,49].
On the other hand, the Emi1 fragments lacking the C-terminal
tail do not inhibit the E2C-mediated ubiquitin chain elongation.
Nevertheless, point mutations within the ZBR domain in Emi1
decrease the inhibitory activity against E2C-mediated ubiquitin
chain elongation [41,48]. Moreover, mutations of the putative
zinc-coordinating amino acid residues within the ZBR domain of
Emi2 disrupt its CSF activity [40,47,50,51]. These results suggested
that the ZBR domains of Emi1/Emi2 contribute to their inhibitory
activities, although the functional mechanisms of the ZBR domain
have not been clariﬁed [52].
Emi1 and Emi2 co-immunoprecipitated with a recombinant
coactivator (Cdc20 or Cdh1) in vitro [26,53]. The DB–ZBR–RL frag-
ment of Emi1 co-immunoprecipitated with the N-terminal frag-
ment of Cdc20 (Cdc20-NT), while the deletion of the ZBR domain
impaired the Cdc20-NT binding ability [45,53] The Cdc20-NT con-
tains the C-box motif, which is shared with Cdh1 and involved inbinding to the core APC/C [9,13]. Nevertheless, Emi1 does not
impair the substrate binding of APC/C [48] and the location of
the ZBR domain of Emi1 is distant from that of Cdh1 on APC/C
[41]. Therefore, the functional purpose of the binding of the ZBR
domain of Emi1/Emi2 to Cdc20/Cdh1 remained elusive.
In the present study, we provide structural and functional infor-
mation about the Emi2 ZBR domain, toward revealing the poten-
tially novel mechanism for the inhibition of APC/C-Cdc20
activity.
2. Materials and methods
2.1. GenBank accession numbers for multiple amino acid sequence
alignment
The following sequences were obtained: MmEmi2/FBXO43,
NP_001074722.1; HsEmi2/FBXO43, NP_001025031; GgFBXO43,
XP_418357; XlErp1/FBXO43, NP_001093338; DrFBXO43, NP_95
6725; MmEmi1/FBXO5, NP_080271; HsEmi1/FBXO5, NP_0 36309;
GgFBXO5, XP_419681.3; XlEmi1/Fbxo5-a, NP_00 1082122; DrF
BXO5, NP_001003869; HsRNF14/ARA54, NP_001188294; HsRN2
16/TRIAD3, NP_996994; HsRN19A/Dorﬁn, NP_056250; HsRN
F31/ZIBRA/HOIP, NP_060469; MmPRKN2/Parkin, NP_057903;
HsPRKN2/Parkin, NP_004553; HsARI1/HHARI, NP_0 05735; HsR1
44B/p53RFP, NP877434; HsCUL9/PARC, NP_055904. Abbreviations
for species names areMm,Mus musculus (mouse); Hs, Homo sapiens
(human); Gg, Gallus gallus (chicken); Xl, Xenopus laevis (African
clawed frog); Dr, Danio rerio (zebraﬁsh). Multiple sequence align-
ments were optimized using the ClustalW program.
2.2. Full-length cDNA clones
The coding sequences (CDSs) corresponding to Emi2, Emi1, and
Cdc20 (GenBank: NP_075712) were obtained from mouse mII
oocytes, as described previously [26]. The CDS of E2C was derived
from the RIKEN full-length enriched mouse cDNA library (Clone ID:
1110015A16), and the CDSs for APC/C subunits ANAPC2 (GenBank:
NP_780509.2), ANAPC11 (GenBank: NP_001033319), and
ANAPC10 (GenBank: NP_081180) were ampliﬁed by PCR from
the Mouse 17-day Embryo Marathon-Ready cDNA library (Clon-
tech, Takara). The target DNA fragments were subcloned into the
pCR2.1 TOPO vector (Invitrogen, Life Technologies) or appropriate
expression vectors.
2.3. Cell culture and phenotypic analysis
HEK293T cells (RIKEN Cell Bank code: RCB2202) were cultured
at 37 C with a 5% CO2 atmosphere in Dulbecco’s modiﬁed Eagle’s
medium, containing 10% (v/v) heat-inactivated bovine serum and
supplemented with penicillin (10 U/ml) and streptomycin (10 lg/
ml).
The target Emi2 or Emi1 cDNA fragments were inserted into the
pAcGFP1-Hyg-C1 vector (Clontech, Takara) to generate the AcGFP-
fusion proteins, and the plasmids were transfected into HEK293T
cells using Lipofectamine LTX (Invitrogen, Life Technologies),
according to the manufacturer’s instructions. At 24 h post-trans-
fection, the medium was replaced with fresh normal culture med-
ium, and the cells were incubated for an additional 30–48 h (2–
3 days post-transfection).
To label the nuclear and chromosomal DNA for aneuploidy, live
cells were stained with Hoechst 33342 (Dojindo). Mitotic morphol-
ogy was observed by ﬂuorescent microscopy (Olympus) with an
Aqua Cosmos system (Hamamatsu Photonics).
For immunoﬂuorescence (IF), HEK293T cells (2.5  105 cells per
well) were plated onto collagen-coated square coverslips in 6-well
dishes, and incubated for 18–20 h before transfection. At 2 days
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30 min at room temperature (RT) in 4% (w/v) PFA-PBS. After wash-
ing twice with PBS, the cells were permeabilized for 2 min with
50 lg/ml digitonin-PBS, washed twice again, and then quenched
in 50 mM ammonium chloride-PBS for 5 min. After blocking with
0.1% gelatin-PBS for 5 min, the cells were incubated for 1–1.5 h
at RT with primary antibodies diluted in 0.1% gelatin-PBS. The cells
were washed three times with PBS, and subsequently incubated for
30 min at RT with Alexa Fluor-conjugated secondary antibodies
(Molecular Probes, Invitrogen/Life Technologies) diluted in 0.1%
gelatin-PBS. For the analysis of the subcellular localization of
AcGFP-fusion constructs in mitotic metaphase cells, we performed
IF using Alexa Fluor 647-labeled anti-a-tubulin antibodies (Santa
Cruz Biotechnology) against the mitotic spindle and Hoechst
33422-labeled chromosomes, and visualized the cells with an
LSM 510 confocal laser scanning microscope (Carl Zeiss). For the
colocalization analysis of AcGFP-Emi2 ZBR–RL and the core APC/
C, we used Alexa Fluor 647-labeled anti-ANAPC2 antibodies (Santa
Cruz Biotechnology), and subsequently collected sequential z-stack
images by using the LSM 510 system in the multi-track mode. The
3D reconstruction was created by sequentially capturing images
within a series of z-planes.
To characterize the cell cycle phase by FACS (ﬂuorescence acti-
vated cell sorting), the transfectants were ﬁxed with 1% parafor-
maldehyde (PFA)-PBS for 30 min at 4 C, washed twice with PBS,
and centrifuged. The cell pellets were subsequently resuspended
in cold 70% ethanol and incubated for 2 h at 4 C. These ﬁxed cells
were stained with propidium iodide (PI), and analyzed by FACSCal-
ibur and the CELLQuest software (BD Biosciences).
2.4. Western blotting (WB) of cell extracts
APC/C inhibition in cells expressing the ZBR–RL fragment of
Emi2 was examined by comparing the CCRP levels between the
AcGFP-Blank vector and the AcGFP-Emi2 fragment fusion transfec-
tants. At 2 days post-transfection, the cells were collected, washed
once with PBS, resuspended in lysis buffer [20 mM Tris–HCl buffer
(pH 8.0), containing 1% Triton X-100, 150 mM NaCl, and protease
inhibitor mixture (Roche Applied Science)], and incubated on ice
for 30 min. The resulting cell lysates were centrifuged at
15,000 rpm for 15 min at 4 C, fractionated by SDS–PAGE, and elec-
troblotted onto a PVDF membrane. The membranes were subse-
quently blocked with skim milk prepared with TBS-Tween, and
immunodetection was performed using the Immobilon Chemilu-
minescent Substrate Kit (Merck Millipore). To assess APC/C inhibi-
tion in cells expressing the AcGFP-Emi2 ZBR–RL, the following
primary antibodies were employed for WB: anti-CycB1 antibody
(V152; MBL) and anti-securin antibody (DCS-280; MBL) to mea-
sure endogenous CycB1 and securin levels, respectively; anti-GFP
antibody (JL-8; Clontech, Takara) to monitor AcGFP fusion protein
expression; and anti-a-tubulin antibody (DM1A; Sigma–Aldrich)
as a loading control.
2.5. Immunoprecipitation (IP) assays
The in vitro binding of the Emi2 fragment to the substrate rec-
ognition catalytic module subunits of APC/C was analyzed by co-
IP (Supplementary Fig. S1A). Mouse cDNAs were subcloned into
the T7 expression vector, pcDNA3.1/myc-His (Invitrogen, Life Tech-
nologies), to generate Myc-tagged prey proteins: ANAPC2,
ANAPC2-CT (C-terminus; residues 337–837 of mouse ANAPC2, cor-
responding to the cullin-homology region), ANAPC11, ANAPC10,
and Cdc20. To generate the double HA-tagged bait protein, the
cDNA corresponding to the F-box–DB–ZBR–RL fragment of mouse
Emi2 (residues 251–641) was subcloned into the tag sequence-
modiﬁed pcDNA3.1/myc-His vector. Recombinant proteins wereproduced by T7-driven in vitro synthesis, using the TNT Quick Cou-
pled Transcription/Translation System (Promega), and were par-
tially puriﬁed using the MagZ Protein Puriﬁcation System
(Promega), according to the manufacturer’s recommendations.
Subsequently, 100 ll portions of the MagZ-puriﬁed bait proteins,
in 1 ml of binding buffer [20 mM Tris–HCl buffer (pH 8.0), contain-
ing 150 mM NaCl, and 0.01% NP-40], were incubated with anti-HA
afﬁnity resin (Roche Applied Science) for 2 h. The unbound species
were removed by washing, and the bait proteins were subse-
quently mixed and incubated with the prey proteins for 18–20 h
at 4 C. Immunocomplexes were collected by centrifugation
(16,000g at 4 C for 5 min), washed, and separated by 10% SDS–
PAGE, and the labeled proteins were detected by WB with anti-
HA (16B12; Covance) or anti-Myc (9B11; Cell Signaling Technol-
ogy) antibodies.
To test the binding of the AcGFP-Emi2 fragment fusion pro-
teins to APC/C and/or Cdc20, a binding assay was performed
using cell extracts from HEK293T transfectants (Fig. 2C and D).
HEK293T cells were transfected in 6-well plates. At 2 days post-
transfection, the cells were lysed in 500 ll of IP buffer [50 mM
Tris–HCl buffer (pH 8.0), 150 mM NaCl, 0.1% NP-40, and Complete
EDTA-free Protease Inhibitor Cocktail (Roche Applied Science)]
per plate. To pre-clear the lysates, Protein G Mag Sepharose (GE
Healthcare) magnetic beads were added, and the lysates were
incubated at 4 C for 45 min on an orbital shaker. Subsequently,
the pre-cleared lysates were subjected to co-IP. Following an
incubation with 0.5 ll of anti-Cdc20 (mouse monoclonal antibody
AR12; MBL) or anti-GFP (Living Colors Full-Length A.v. Polyclonal
Antibody; Clontech, Takara) for 45 min at 4 C with rotation, Pro-
tein G magnetic beads were added and incubated for 45 min at
4 C with rotation. For the detection of co-immunoprecipitates,
the magnetic beads were isolated, washed four times with IP
buffer, and subjected to WB using antibodies against Cdc20
(rabbit polyclonal antibody; Santa Cruz Biotechnology), GFP
(mouse monoclonal antibody JIL-8; Clontech, Takara), and
ANAPC3/Cdc27 (mouse monoclonal antibody C-4; Santa Cruz
Biotechnology).
2.6. Ubiquitylation assay
In vitro ubiquitylation assays were performed in a volume of
25 ll. For the experiments shown in Fig. 5, reaction mixtures con-
taining 10 ng/ll GST-E1 (Calbiochem, Merk Millipore), 20 ng/ll
E2C (UBE2C), 20 ng/ll HT-ANAPC2–11 (prepared using a baculovi-
rus expression system [21], and 100 ng/ll FLAG-tagged ubiquitin
(Sigma–Aldrich) were incubated with 40 ng/ll of Emi2 C-terminal
fragments at 30 C for 0, 5, 15, or 45 min, in 20 mM HEPES-NaOH
(pH 7.4), 5 mMMgCl2, and 5 mM ATP. For subsequent experiments
using the cell-free-synthesized ANAPC2CW–11 complex as the min-
imum CRL E3 module of APC/C (mCRLA) shown in Fig. 6, reaction
mixtures containing 2 ng/ll GST-E1, 5 ng/ll E2C, 40 ng/ll mCRLA,
and 50 ng/ll FLAG-tagged ubiquitin (Sigma–Aldrich) were incu-
bated with 30 ng/ll of Emi2 fragments at 30 C for 0, 5, or
15 min, in 20 mM HEPES-NaOH (pH 8.0), containing 1 mM MgCl2
and 2 mM ATP. The reactions were stopped by adding 25 ll of
3  SDS–PAGE sample loading buffer [5% (w/v) SDS, 250 mM
DTT, 15% (v/v) glycerol, 140 mM Tris–HCl (pH 6.8), and 0.01% (w/
v) bromophenol blue] and incubated at 95 C for 3 min. The ubiq-
uitylation reactions were resolved by SDS–PAGE on a 10–20% gra-
dient gel, followed by WB using anti-FLAG antibodies (M2; Sigma–
Aldrich) and detection with an Immobilon Chemiluminescence
Detection Kit (Merck Millipore). Luminescent signals correspond-
ing to polyubiquitin chains were acquired with the Luminescent
Image Analyzer LAS-3000 (Fujiﬁlm, GE Healthcare), and were
quantiﬁed using the Multi Gauge image analysis program (Fujiﬁlm,
GE Healthcare).
Fig. 1. Exogenous expression of the Emi2 ZBR–RL fragment in proliferating cells causes abnormal cell division. (A) Morphological properties of unﬁxed HEK293T cells
transfected with AcGFP-Emi2 ZBR–RL and AcGFP-Blank control vector. At 2 days post-transfection, cells were observed by exposure to blue light (GFP) and phase contrast
imaging (PhC). The panels on the right show merged images. Scale bar, 50 lm. (B) Fluorescence-activated cell sorting (FACS) analysis of AcGFP-positive cells at 2 days post-
transfection, using propidium iodide DNA staining to determine cell cycle phase: G1, S, or G2/M. NC, not categorized. A stacked bar graph showing the percentage of cells in
each phase of the cell cycle is displayed on the right. (C) Subcellular analysis of sphere-shaped cells expressing AcGFP-Emi2 ZBR–RL. Mitotic spindles were visualized with
Alexa Fluor 633-labeled anti-a-tubulin antibodies (middle) and Hoechst 33422-stained chromosomal DNA (bottom). Scale bar, 10 lm. (D) Western blots (WBs) showing
endogenous CycB1 and securin levels in cell extracts from AcGFP transfectants at 2 days post-transfection. Alpha-tubulin served as a loading control. (E) 3D confocal
microscopy images of cells expressing AcGFP-Emi2 ZBR–RL (green) at M-phase. Alexa Fluor 647-labeled anti-ANAPC2 served as an APC/C marker (magenta). The dark shaded
area in the middle of the cell corresponds to the region of condensed chromosomes in the mitotic spindle. The images represent the xy section with 2 perpendicular lines: the
horizontal line (top) in the xz plane and the vertical line (side) in the yz plane. The central box corresponds to the position of the currently displayed xy plane. Scale bar, 10 lm.
(F) Cells expressing AcGFP-Emi2 ZBR–RL at 3 days post-transfection, stained with Hoechst 33342 for nuclear DNA. Scale bar, 100 lm. (G) Diagram of major morphological
changes observed during the cell cycle progression of HEK293T cells and the inhibition of mitosis by the AcGFP-Emi2 ZBR–RL fusion construct used in the transfection assays.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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catalyzed ubiquitin activation, reactions were performed in the
absence of E2 and E3 and analyzed by WB. For the detection of
non-covalent binding, E1Ub (Supplementary Fig. S4E), reaction
aliquots were quenched in SDS–PAGE loading buffer under reduc-
ing (+DTT) or non-reducing (DTT) conditions, fractionated by
SDS–PAGE and visualized by Coomassie Brilliant Blue (CBB) stain-
ing or WB.
To analyze the ubiquitylation sensitivity of AcGFP-Emi2 ZBR
mutants in cell, HEK293T transfectants were lysed in IP buffer at
3 days post-transfection. Following IP using mouse monoclonal
antibodies, FK2 (BIOMOL, Enzo Life Sciences) or anti-GFP (M)
mixed with Protein G magnetic beads, the IP samples were sub-
jected to WB using a rabbit polyclonal anti-GFP antibody (R).For the preparation of ubiquitin adducts and ubiquitin chain
linkages for mass spectrometry analyses, the reaction products
were resolved by SDS–PAGE and visualized using a SilverQuest Sil-
ver Staining Kit (Invitrogen, Life Technologies), according to the
manufacturer’s protocol, or by standard CBB staining. Gel regions
containing proteins were excised and digested with trypsin
(Sigma–Aldrich) for 20 h at 37 C. The resulting peptides were ana-
lyzed by liquid chromatography–electrospray ionization tandem
mass spectrometry (LC–ESI-MS/MS).
2.7. Protein synthesis and puriﬁcation
The proteins composing the full-length ANAPC2–11 complex,
His6-tagged ANAPC2 and untagged ANAPC11, were coexpressed
Fig. 2. Cellular assays using a series of AcGFP-Emi2 fragment fusion constructs. (A) Diagram of the Emi2 C-terminal constructs. Numbers correspond to amino acid positions
of mouse (Mm) Emi2. (B) Morphological phenotypes of HEK293T cells transfected with AcGFP-Emi2 fragment fusion constructs (see also panel A) at 2- and 3-days post-
transfection. Scale bar, 100 lm. The boxes in the bottom left corners show close-up views of the cells at 2 days post-transfection. Scale bar, 50 lm. Yellow arrows indicate
multinucleated cells and giant cells. (C) and (D) Interactions between endogenous APC/C and/or Cdc20 with a series of AcGFP-Emi2 fragment fusion constructs in the cell. Cell
extracts from the indicated HEK293T transfectants were used for co-IPs with an anti-GFP antibody (C) or an anti-Cdc20 antibody (D). WBs of the immunoprecipitates (IP) and
cell lysates were probed with the indicated antibodies. M, mouse monoclonal antibodies; R, rabbit polyclonal antibodies. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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(Invitrogen, Life Technologies) and copuriﬁed according to the
method of Huang et al. [21], with the exception that TALON
resin (Clontech, Takara) was used for the ﬁrst capture step,
instead of Ni-Agarose. The Emi2 fragments, E2C and mCRLA,
were synthesized using a cell-free protein expression system
[54] and subsequently puriﬁed using an AKTA 10S system (GE
Healthcare), as follows. The protein fragments were puriﬁed by
ﬁrst adsorbing each reaction mixture to a HisTrap HP column
(GE Healthcare), which was washed with concentration gradient
buffer [50 mM Tris–HCl buffer (pH 8.0) containing 1 M NaCl and
10 mM imidazole]. The protein was eluted with a concentration
gradient of imidazole (from 10 to 500 mM) in elution buffer
[50 mM Tris–HCl buffer (pH 8.0) containing 0.5 M NaCl], andthe imidazole was removed by overnight dialysis at 4 C in wash
buffer. The His-tag was removed by an incubation at 4 C for
20 h with TEV protease. The resulting untagged proteins were
puriﬁed by ion exchange chromatography using a HiTrap column
(GE Healthcare) and gel ﬁltration using a HiLoad Superdex 75 pg
16/60 column (GE Healthcare), with the ﬁnal buffer [20 mM
Tris–HCl buffer (pH 8.0), containing 150 mM NaCl, and 2 mM
DTT]. In the cases, where the synthesized protein region that
contained a zinc-ﬁnger domain (mCRLA and ZBRs), ZnCl2 was
added to the puriﬁcation buffers at a ﬁnal concentration of
20 lM.
The concentrations of the puriﬁed proteins were determined by
measuring the absorbance at 280 nm with a NanoDrop
spectrophotometer (Thermo Scientiﬁc).
Fig. 3. Structural and functional comparisons of the Emi1 and Emi2 ZBR domains. (A) and (B) Solution structure of the Emi2 ZBR domain, determined by NMR spectroscopy.
(A) Ribbon-diagram representation of the lowest energy structures, showing two views from different angles. Secondary structure elements (b-strands) are colored
ultramarine blue. Magenta-colored balls represent zinc ions. Numbered positions (orange and violet) indicate the residues coordinating the zinc ions. (B) Superimposition of
the solution structure of the Emi1 ZBR domain (PDB ID, 2M6 N; Frye et al. [41]) and that of the Emi2 ZBR domain (PDB ID, 2RT9; the present study). (C) Multiple sequence
alignment of the ZBR–RL regions from Emi1 and Emi2 orthologs. Mm,Mus musculus (mouse); Hs, Homo sapiens (human); Gg, Gallus gallus (chicken); Xl, Xenopus laevis (African
clawed frog); Dr, Danio rerio (zebraﬁsh). Identical residues are shown in black. Horizontal ultramarine blue arrows represent b-strands, and the residues in shaded boxes
indicate zinc-coordinating residues, related to panel A. Ocher arrows indicate ANAPC2CW-interacting sites in the ZBR–RL region from mouse Emi2, based on NMR chemical
shift perturbation data, related to Supplementary Fig. S2C. The lime line indicates the E2S-like sequence. The olive dashed line indicates the RL residues involved in binding to
ANAPC10 [49]. (D) Morphological phenotypes of HEK293T cells transfected with AcGFP-fusion constructs of the Mm Emi1 ZBR–RL and ZBR fragments at 3 days post-
transfection. Scale bar, 50 lm. (E) Cells expressing AcGFP-Emi2 ZBR and AcGFP-Emi1 ZBR at 3 days post-transfection, stained with Hoechst 33342 for nuclear DNA. Scale bar,
50 lm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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calculations
For the determination of the Emi2 ZBR domain structure by
NMR, the protein samples were prepared as [13C, 15N]-labeled
proteins using a cell-free protein synthesis system, and were sub-
sequently puriﬁed and concentrated in NMR analysis buffer[20 mM Tris–HCl (pH 6.5), 100 mM NaCl, 1 mM DTT, 1 mM
iminodiacetic acid (IDA), 50 lM ZnCl2, 0.02% (w/v) NaN3, and 10%
(v/v) 2H2O]. We solved the solution structure of the Emi2 ZBR
domain by standard NMR methods [55,56].
NMR experiments were performed at 298 K, using Bruker
AVANCE spectrometers equipped with triple-axis gradients oper-
ating at 600 and 800 MHz, with the 13C- and 15N-doubly labeled
Fig. 4. Mutations of Emi2 ZBR domain surface residues. (A) and (B) Effects of single amino acid substitutions of the ZBR domain within AcGFP-Emi2 ZBR–RL and AcGFP-Emi2
ZBR on the abnormal mitotic phenotype in HEK293T cells at 3 days post-transfection. Morphological properties of the cells expressing the indicated mutants, the ZBR–RL
fragment (A), or the ZBR fragment (B). WT, wild type sequence. Scale bar, 50 lm. (C) and (D) Interactions between endogenous Cdc20 and the ZBR mutants of AcGFP-Emi2
fragments in the cell. Cell extracts from the indicated HEK293T transfectants were used for co-IP with an anti-Cdc20 antibody. White lines indicate the gaps between lanes.
(E) Characterization of amino acid residues on the surface of the Emi2 ZBR domain. (F–H) Hypothetical mechanism for the Emi2 ZBR-induced abnormal cell division
phenotype, by destabilizing the association of Cdc20 with the APC/C core complex. The ZBR domain of Emi2 binds to the APC/C coactivator Cdc20, partially dissociates it from
the core APC/C (red-brown) (F), and furthermore prevents the re-association of APC/CCdc20 (cyan) (G). Complete association of Cdc20 with APC/C (active mode) for the cell
cycle regulatory protein (CCRP) ubiquitylation, illustrated (H) for comparison. The ZBR domain has a Cdc20-independent APC/C inhibitory activity (cobalt blue). The C-
terminal region of contributes to anchoring the ZBR domain to the cullin-RING module of APC/C (ocher), shown in Fig. 3C. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. The ZBR–RL fragment of Emi2 inhibits ubiquitin chain elongation by ANAPC2–11 in combination with E2C. (A) Schematic diagram showing the core enzymatic
reaction of APC/C for polyubiquitin chain (poly-Ub) formation. E1 and the combination of E2C with E3 ligase (ANAPC2–11) generates activated ubiquitin (Ub) for ubiquitin
chain elongation. Details of the ubiquitylation factors are described in the Section 3. (B) In vitro ubiquitylation reactions using N-terminal FLAG-tagged ubiquitin (UbFLAG) and
the E1-E2C-E3 system shown in panel A. UbFLAG adducts and UbFLAG chains were detected by anti-FLAGWestern blotting (WB). The WB with the anti-E2C antibody shows the
auto-ubiquitylation activity of E2C. (C) Inhibition of ubiquitin chain elongation by the indicated Emi2 C-terminal fragments. Numbers correspond to amino acid positions of
mouse (Mm,Mus musculus) Emi2. (D) Inhibition of ubiquitin chain elongation by the ZBR–RL fragments fromMm Emi2 (residues 547–641) and Mm Emi1 (residues 326–421).
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and 13C chemical shifts were referenced to the frequency of the
2H lock resonance of water. A series of 2D and 3D standard triple
resonance NMR experiments were recorded [56], and 2D [1H,
15N]-HSQC and 3D HBHA(CO)NH, HNCA, HN(CO)CA, HNCACB,
and CBCA(CO)NH spectra were used for sequence-speciﬁc
backbone assignments. Side-chain assignments were obtained
using 2D [1H, 15N]-HSQC and 3D HBHA(CO)NH, H(CCCO)NH,
(H)CC(CO)NH, HCCH-COSY, HCH-TOCSY, and (H)CCH-TOCSY spec-
tra. For consistency, 3D 15N- and 13C-edited NOESY-HSQC spectra
were also obtained, to check the chemical shift assignments. All
NMR data were processed with the NMRPipe program [57]. Lin-
ear prediction and zero ﬁlling were used in the indirect dimen-
sions, to obtain higher resolution. The KUJIRA [58] and
NMRView [59] programs were used for NMR spectral analysis.
NOE data from 15N- and 13C-edited 3D NOESY spectra were used
for the structure calculations. Automated NOE cross-peak
assignments [60] and structure calculations with torsion angle
dynamics were performed using the CYANA1.0.7 software
package. Dihedral angle restraints were derived using the
TALOS program [61], and structures were validated using
PROCHECK-NMR [62]. Graphical analysis was performed with
the MOLMOL or PyMol programs.
More than 20 NOE distance restraints per residue—including
364 long-range distance restraints and the restraints for coordi-
nating the zinc ion—were used for the ﬁnal structure calculationswith the CYANA 2.1 program [63]. The ﬁnal structures were
energy-reﬁned with the AMBER12 program [64], using the gener-
alized Born model and the Amber ff99SB force ﬁeld, as described
previously [65]. The ﬁnal 20 energy-minimized conformers that
represent the solution structure of the Emi2 ZBR domain are well
deﬁned and show excellent agreement with the experimental
data (Supplementary Table S1; Supplementary Fig. S2B). The pre-
cision of the structure is indicated by the RMSD values of the
mean coordinates of 0.31 Å for the backbone and 1.11 Å for all
heavy atoms of residues A569–R615. The quality of the structure
is also reﬂected by the fact that 80.8% of the (/, w) backbone tor-
sion angle pairs were found in the most favored region, and
19.3% were within the additionally allowed regions of the Rama-
chandran plot, as determined by the PROCHECK-NMR program
[62].2.9. NMR chemical shift perturbation analysis
For the NMR chemical shift perturbation experiment (Fig. 3C;
Supplementary Fig. S2C), the ANAPC2 fragment corresponding to
the cullin domain and winged-helix (ANAPC2CW) was prepared
as a un-labeled protein using a cell-free system, and was
subsequently puriﬁed and concentrated in NMR analysis buffer
[20 mM Tris–HCl buffer (pH 7.0), containing 100 mM NaCl, 1 mM
DTT, 1 mM IDA, 50 lM ZnCl2, 0.02% (w/v) NaN3, and 10% (v/v)
Fig. 6. Inhibition of ubiquitin chain elongation by the Emi2 ZBR-domain fragment. (A) Diagram representing the minimized CRL-type E3 module of APC/C, mCRLA. (B) Puriﬁed
protein components of the in vitro ubiquitylation system using mCRLA. The SDS–PAGE gel was stained with Oriole ﬂuorescent gel stain. (C) In vitro ubiquitylation inhibition
assay of the Emi2 ZBR–RL fragment, using the mCRLA system. Bands marked with asterisks contain ubiquitin dimers and partially ubiquitylated Emi2 fragments. (D) WB
showing the concentration-dependent inhibitory effect of the ZBR fragment of Emi2 against the mCRLA-mediated ubiquitin chain elongation. (E) In vitro assay for the
inhibitory activities of the ZBR fragments from mouse Emi2 (residues 566–617) and Emi1 (residues 345–396) against ubiquitin elongation by the mCRLA system. (F) and (G)
Comparison of the inhibitory activities of the Emi2 ZBR–RL and ZBR fragments against ubiquitin chain elongation. (F) WB bands, visualized using a luminescent image
analyzer system. (G) Graphs representing the production of poly-Ub, determined by measuring the chemiluminescent-signal intensities (arbitrary units, AU) of WBs, using
the Image Gauge software. Baseline levels were adjusted by subtracting the time-zero value from all other time-point values. Each graph represents the mean ± SEM (n = 6;
the other 5 WBs are shown in Supplementary Fig. S5A). (H) WB showing the effects of the K576M and K587Mmutations on the inhibition of ubiquitin chain elongation by the
Emi2 ZBR fragment. (I) Production levels of poly-Ub, representing the chemiluminescent intensities (AU) of the bands shown in panel H. Results represent the mean ± SEM of
3 independent experiments (the other two WBs are shown in Supplementary Fig. S5C).
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were recorded while increasing the peptide concentration relative
to that of the [15N, 13C]-labeled Emi2 fragments (35 lM), to ﬁnalmolar ratios of 1:0.1 to 1:1.0. The 2D-HSQC spectra collected at each
titration point were normalized, and the chemical shift changes
were calculated.
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The Protein Data Bank (PDB) ID for the solution structure of the
Emi2 ZBR domain reported in this paper is 2RT9. The chemical shift
assignments have been deposited in the BioMagResBank (BMRB)
database (accession code, 11529).
3. Results and discussion
3.1. Overexpression of the Emi2 ZBR–RL fragment results in
morphological abnormalities and increased G2/M content
In the case of the mitotic cell-cycle regulator Emi1, the minimal
region required for in vitro APC/C inhibition is reportedly its ZBR–
RL region, encompassing the ZBR domain and the C-terminal RL
residues [48]. For a comparison between Emi1 and Emi2, we exam-
ined the effects of the exogenous expression of the corresponding
ZBR–RL fragment of Emi2 on mitotic events. Under normal prolif-
eration conditions, the human embryonic kidney cell-line 293T
(HEK293T) undergoes a dramatic cell shape change during the
mitotic phase/M phase, which is a relatively short period in the cell
cycle period (less than 1 h). Therefore, we transfected HEK293T
cells with the plasmid vector expressing the Emi2 ZBR–RL frag-
ment as a fusion protein with the Aequorea coerulescens green ﬂuo-
rescent protein (AcGFP), under the control of the cytomegalovirus-
immediate early (CMV-IE) promoter, a strong and constitutively
active promoter.
The cells expressing AcGFP-Emi2 ZBR–RL exhibited sphere- or
ball-like shapes at two days post-transfection (Fig. 1A). A ﬂuores-
cence-activated cell sorting (FACS) analysis revealed that the cells
expressing AcGFP-Emi2 ZBR–RL exhibited a signiﬁcantly increased
population in the G2/M phase and an increased DNA content
(Fig. 1B). Subcellular analyses with simultaneous visualization of
the mitotic spindle and chromosomes conﬁrmed that the sphere-
shaped cells were in M-phase (Fig. 1C). In addition, the character-
istic accumulation of AcGFP-Emi2 ZBR–RL at the pericentrosomal
region of the mitotic spindle was observed. Western blotting
(WB) indicated that the levels of cyclin B1 (CycB1) and securin
(M-phase substrates of APC/C) in the cell extracts from the
AcGFP-Emi2 ZBR–RL transfectants were higher than those of the
blank control (Fig. 1D). APC/C is localized to the mitotic spindle
in M phase and at the nucleus in interphase [66,67] and AcGFP-
Emi2 ZBR–RL exhibited similar subcellular distributions. ANAPC2
exists in the cell as a stable complex with ANAPC11, for the cul-
lin-RING ligase (CRL)-type E3 catalytic module of APC/C. Notably,
3D-reconstruction images of the sphere-shaped M-phase cells
revealed that the AcGFP-Emi2 ZBR–RL immunoﬂuorescence (IF)
signals overlap with those of ANAPC2 around the condensed chro-
mosome in the mitotic spindle (Fig. 1E). After culturing for 24 h
further, multinucleated giant cells were frequently seen in the
AcGFP-Emi2 ZBR–RL transfectants (Fig. 1F). Collectively, these
results showed that the overexpression of the Emi2 ZBR–RL frag-
ment in HEK293T cells leads to mitotic abnormalities (a schematic
representation is shown in Fig. 1G).
3.2. The ZBR fragment of Emi2 induces abnormal cell division and
inhibits Cdc20 binding to the core APC/C
We compared the ZBR–RL fragment with the F-box–DB–ZBR–
RL, DB–ZBR–RL, and ZBR fragments (Fig. 2A), with respect to the
effects of their expression on mitotic events. First, we conﬁrmed,
by a co-immunoprecipitation (co-IP) assay using in vitro-translated
proteins (Supplementary Fig. S1), that the F-box–DB–ZBR–RL frag-
ment of Emi2 binds to the full-length ANAPC2, as reported for Emi1
[48], and its C-terminal cullin-like sequence fragment. Most of the
transfectants expressing the AcGFP-fused F-box–DB–ZBR–RL orDB–ZBR–RL fragment exhibited sphere- or ball-like shapes at
2 days post-transfection, and stopped cell proliferation (Fig. 2B).
The cells expressing the ZBR fragment at 3 days post-transfection
formed giant cells, due to the failure of nuclear division, as also
detected with the ZBR–RL fragment at 2–3 days post-transfection
(Fig. 2B, right). Therefore, the cell-division inhibiting activities
are in the order ZBR < ZBR–RL < DB–ZBR–RL 6 F-box–DB–ZBR–RL.
It should be emphasized here that the ZBR fragment also exerted
the cell-division inhibiting activity, although it was weaker than
those of the longer fragments.
The F-box–DB–ZBR–RL and DB–ZBR–RL fragments exhibited
stronger phenotypes than that of the ZBR–RL fragment (Fig. 2B).
Correspondingly, we found that the AcGFP-fused Emi2 F-box–
DB–ZBR–RL fragment binds to APC/C more tightly than the ZBR–
RL fragment in co-IP analyses of cell extracts of the transfectants
with an anti-GFP antibody (Fig. 2C). In contrast, the binding of
the ZBR fragment to APC/C was not detectable by this analysis
(Fig. 2C). These results are consistent with the previous report
[42] that the C-terminal tail containing the RL residues of Emi2 is
sufﬁcient for its APC/C binding.
The Cdc20-bound APC/C (APC/C-Cdc20) controls the G2/M tran-
sition in cell division. The F-box–DB–ZBR–RL fragment of Emi2 is
sufﬁcient for mII arrest [50], and actually binds to the APC/C coac-
tivator Cdc20 in vitro (Supplementary Fig. S1). Therefore, we exam-
ined whether the Emi2 ZBR fragment interacts with Cdc20 in the
cell, by a co-IP analysis with an anti-Cdc20 antibody that precipi-
tates both Cdc20 and Cdc20-bound APC/C. In fact, all of the F-
box–DB–ZBR–RL, ZBR–RL, and ZBR fragments co-precipitated with
Cdc20 (Fig. 2D). On the other hand, the binding of the ZBR fragment
to APC/C was not detectable by the co-IP analysis of cell extracts of
the AcGFP-Emi2 fragment transfectants with an anti-GFP antibody
(Fig. 2C). These results indicated that the ZBR domain is responsi-
ble for Cdc20 binding. Intriguingly, the Cdc20 bound with the ZBR
fragment hardly co-precipitated with APC/C (Fig. 2D). We specu-
late that the mechanism underlying the phenotype at 3 days
post-transfection of the Emi2 ZBR fragment may be that the ZBR
fragment binds to Cdc20, and dissociates it from APC/C.
On the other hand, the ZBR–RL and F-box–DB–ZBR–RL frag-
ments exhibited weaker Cdc20 separation activities, probably
because the C-terminal tail connects the ZBRCdc20 complex to
ACP/C, and the F-box–DB region reinforces the interaction
(Fig. 2C). In general, the F-box and DB motifs mediate the recogni-
tion of targets, such as CCRP, by the E3 ubiquitin ligases, including
APC/C, for degradation by the ubiquitin–proteasome system (UPS)
in cells. The F-box and DB motifs may trigger the initial binding of
Emi2 to the Cdc20-bound APC/C to enhance the inhibitory mecha-
nism further, rather than exerting inhibition by the classical
pseudosubstrate mechanism.
3.3. Structural and functional analyses of the Emi2 ZBR–RL region
The [1H-15N] HSQC spectra of the Emi2 ZBR–RL fragment
showed well-dispersed resonances, with sharp resonances clus-
tered around 8.3 ppm (1H chemical-shift value). After the main-
chain resonance assignment, the region spanning residues 566–
617 of mouse Emi2 (the ZBR fragment) produced well-dispersed
resonances with uniform signal intensities (Supplementary
Fig. S2A, left). In contrast, the sharp resonances clustered around
8.3 ppm originated from the C-terminal residues 618–641, sug-
gesting that this region is ﬂexible and disordered (Supplementary
Fig. S2A, right).
The solution structure of the Emi2 ZBR fragment was deter-
mined by multidimensional NMR spectroscopy (Fig. 3A; Supple-
mentary Fig. S2B; Supplementary Table S1). The N-terminus of
the Emi2 ZBR domain comprises two successive b-hairpins: the
ﬁrst is composed of b1 (K571–P572) and b2 (P579–A580), and
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The ﬁrst zinc ion is coordinated with four ligand residues (C573
and C576 at the tip of the ﬁrst b-hairpin, and C591 and C596 at
the tip of the second b-hairpin). The two b-hairpins are tightly
bound to each other, and form a scissor-like structure. The b5
strand (D599–C601) associates with the b4 strand in an anti-paral-
lel manner, to form the C-terminal GAG knuckle-like zinc-binding
site, including the C601, C604, H609, and C614 residues (Fig. 3A
and C). The Emi2 ZBR domain adopts the same topology as the
Emi1 ZBR domain (Fig. 3B).
The co-IP and IF analyses both indicated that the Emi2 ZBR–RL
fragment interacts with ANAPC2 (Fig. 1E; Supplementary Fig. S1A).
NMR titration experiments, using 13C- and 15N-labeled Emi2 ZBR–
RL, revealed that the R615, G617, S624, V627, L628, A632, Q633,
and K639 residues in the Emi2 ZBR–RL region interact with the cul-
lin–winged-helix subdomain of ANAPC2 (Fig. 3C; Supplementary
Fig. S2C). On the other hand, no chemical shift changes were
observed for the NMR peaks corresponding to the RL residues at
the C-terminus, which is required for ANAPC10 binding [42,49].
Therefore, the residues 615–627, corresponding to the region
between the ZBR domain and the C-terminal RL residues [the
‘‘post-ZBR’’ (PZ) region], shown with a dashed line in Fig. 3C, are
involved in the binding of Emi2 to ANAPC2. According to the
cryo-EM analyses of APC/C, which indicated that ANAPC10 con-
nects to ANAPC2 (ANAPC2–11 subcomplex) within intact APC/C
[18,68,69], we consider that the RL residues at the C-terminus of
Emi2 bind to the ANAPC10, whereas the PZ region interacts with
the cullin-winged helix subdomain of ANAPC2.
This architecture of the ZBR domain and the C-terminal tail con-
sisting of the PZ region and the RL residues is evolutionally con-
served in the Emi/Erp family (Fig. 3C; Supplementary Fig. S2D).
We examined the effects of the over-expression of the ZBR–RL
and ZBR fragments of Emi1 on cell division. The cells expressing
the AcGFP-fused Emi1 ZBR–RL fragment exhibited sphere- or
ball-like shapes at three days post-transfection (Fig. 3D). However,
in contrast to the phenotypes of cells expressing the ZBR fragment
of Emi2, almost all of the cells expressing the ZBR fragment of Emi1
lacked the abnormal mitotic phenotypes, including giant cell for-
mation (Fig. 3E). These results suggested that the roles of the ZBR
domains are different between Emi2 and Emi1.
3.4. Amino acid residues important for the cell-division inhibiting
activity of the Emi2 ZBR domain
To identify the residues in the ZBR domain of Emi2 that are
important for the cell-division inhibiting activity, we introduced
single amino acid substitutions within the ZBR domain in the
ZBR–RL and ZBR fragments. The well-conserved and exposed
amino acid residues among the Emi/Erp ZBR domains were
selected on a structural basis, and the zinc-coordination sites were
excluded (Supplementary Fig. S3A). The effects of these mutations
on the abnormal mitotic phenotype of HEK293T cells transfected
with AcGFP-Emi2 ZBR–RL, the appearance of multinucleated cells
at three days post-transfection (Figs. 1F, 2B), were analyzed as
shown in Fig. 4A. The expression levels of the mutants were similar
to that of the wild type (WT), and the following residues (in the
order of effectiveness) reduced the abnormal mitotic phenotype:
K586 M > K587 MP K571 M > Q577G  C606S. These amino-acid
substitutions within the ZBR domain did not impair the ZBR–
RLAPC/C binding (Supplementary Fig. S3C).
The ZBR fragment of Emi2 lacking the C-terminal tail also
exerted the cell-division inhibiting activity, although it was weaker
than that of the ZBR–RL fragment (Figs. 2B, 3E). Mutations of the
ZBR fragment actually affected the Emi2 ZBR-induced mitotic
abnormality, in the order K586 M > K587 MP Q577G > C606S > K
571 M (Fig. 4B). An analysis of binding in cells revealed that Cdc20co-precipitated with the ZBR fragment, but hardly co-precipitated
with APC/C (Fig. 2D), indicating that the Cdc20ZBR complex negli-
gibly interacts with APC/C. We then examined whether these
mutations impaired the binding of the ZBR fragment to Cdc20, by
an in vivo co-IP analysis. The K571M, Q577G, K586M, and C606S
mutants hardly bound to Cdc20, whereas K587M bound to Cdc20
as well as the WT (Fig. 4C). Therefore, four residues, K571, Q577,
K586, and C606, but not K587, are involved in the Cdc20 binding.
Thus, the effects of the K571M, Q577G, K586M, and C606S muta-
tions on the Emi2 ZBR-induced mitotic abnormality are correlated
with the effects on the Cdc20 binding.
In the case of the ZBR–RL fragment, not only K587M but also the
K571M, Q577G, and C606S mutants co-immunoprecipitated with
Cdc20 (Fig. 4D), indicating that the K571M, Q577G, and C606S
mutants are anchored to APC/C through the C-terminal tail, consist-
ing of the PZ region and the RL residues, and Cdc20 binds normally
to the core APC/C. The K586M mutation impairs the Cdc20APC/C
interaction in both the ZBR and ZBR–RL fragments (Fig. 4C and D),
while this mutation most strongly reduces the Emi2 ZBR-induced
mitotic abnormality. Interestingly, K571, Q577, and C606, but not
K586, are located on one side of the domain surface (Fig. 4E). There-
fore K586 seems to contribute robustly to prevent Cdc20 re-associ-
ationwith the core APC/C, but minimally to the putative interaction
with Cdc20 in the APC/C-Cdc20.
In contrast to the results reported by Wu et al. (2007) that Emi2
can bind to the APC/C core complex in the absence of Cdc20 [70],
Sako et al. (2014) recently indicated that Cdc20 is required for the
APC/C-Emi2 interaction before cytostatic arrest release in unfertil-
ized Xenopus eggs [49]. In our present study, the Cdc20 bound with
the ZBR fragment hardly co-precipitated with APC/C (Fig. 3B) and
the PZ region of Emi2 is likely to connect the ZBRCdc20 complex
to ACP/C (Fig. 3C). Nevertheless, overexpression of the ZBR frag-
ment of Emi2 induces cell division abnormalities (Figs. 2B, 3E).
Therefore, we propose amodel for the inhibition of normalM-phase
progression. First, the Emi2 ZBR domain binds to Cdc20, and at least
partly disrupts the association of Cdc20 with APC/C (Fig. 4F). Subse-
quently, the Emi2 ZBR domain separates Cdc20 from the APC/C core
complex (Fig. 4G), thus preventing their complete association for
the full activation of APC/C-Cdc20 (Fig. 4H).
Finally, the effect of the K587M mutation on the Emi2 ZBR-
induced mitotic abnormality (Fig. 4A and B) is distinct from those
of the other mutations, as the K587M mutant retains the ability to
bind Cdc20 (Fig. 4C and D). The side chain of K587 is oriented
oppositely, as compared with that of K586 (Fig. 4E, the second
panel). Therefore, the Emi2 ZBR-induced mitotic abnormality is
the consequence of two different mechanisms. In this context, it
was recently reported that the ZBR–RL region of Emi1 inhibits
the E2C-mediated ubiquitin chain elongation with the intact
APC/C polyubiquitylation system [41,48].
3.5. The ZBR–RL fragment of Emi2 inhibits the ubiquitin chain
elongation by the ANAPC2–11 subcomplex in combination with E2C
To examine the Cdc20-independent APC/C inhibition by the
ZBR–RL fragment of Emi2, we performed the in vitro ubiquitylation
assay using the puriﬁed recombinant APC/C core enzymatic com-
ponents. The fundamental ubiquitylation reaction was performed
by the set of three enzymes, E1, E2C, and E3, without a speciﬁc sub-
strate and its recognition factors (Fig. 5A and B; Supplementary
Fig. S4). The E3 catalytic subcomplex of APC/C, ANAPC2–11, was
prepared using a baculovirus expression system, according to the
method reported by Huang et al. [21]. The ubiquitin chain-initiat-
ing E2, E2C (also known as UBE2C or UbcH10), is the genetically
validated E2 partner for APC/C [71,72], and E2C interacts with
ANAPC2 [20,73]. In this reaction, we could observe E2C-mediated
ubiquitin chain elongation, and distinguish it from the auto-ubiq-
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etry analysis of the poly-ubiquitin linkage type in our system indi-
cated that K11 and K48 are the major linkages, with the former
more abundant than the latter. Both ubiquitin linkage types are
produced in CycB1 polyubiquitylation by the combined activities
of the intact APC/C and E2C in vitro [74].
This in vitro polyubiquitylation assay unambiguously revealed
that the Emi2 fragment corresponding to the ZBR–RL region inhib-
its the ubiquitin chain elongation in the absence of the natural tar-
get protein, the coactivator Cdc20, ANAPC10, and ubiquitin chain-
extending E2, E2S/UBE2S (Fig. 5C). In addition, the in vitro assay
conﬁrmed that the ZBR–RL region of Emi1 also inhibits ubiquitin
chain elongation (Fig. 5D), as reported with the intact APC/C poly-
ubiquitylation system, in combination with E2C [41,48].
3.6. The ZBR domain of Emi2 inhibits the ubiquitylation by the APC/C
cullin-RING module combined with E2C
The ZBR–RL fragment of Emi2 interacts with the cullin–winged-
helix subdomain of ANAPC2, ANAPC2CW, as described above
(Fig. 3C; Supplementary Fig. S2C). The ANAPC2CW region is report-
edly sufﬁcient for E2C binding and E3 activity [20]. We therefore
established an in vitro polyubiquitylation system using the mini-
mum cullin-RING ligase (CRL) module of APC/C (mCRLA), which
was prepared by the co-expression of ANAPC2CW and ANAPC11
in an E. coli cell-free protein synthesis system (Fig. 6A and B).
The mCRLA exhibited the CRL E3 activity of APC/C to elongate ubiq-
uitin chains, and Emi2 ZBR–RL signiﬁcantly decreased the rate of
mCRLA-mediated ubiquitin chain elongation (Fig. 6C; Supplemen-
tary Fig. S5A). Our mCRLA protein lacks eukaryotic posttransla-
tional modiﬁcations, whereas most APC/C subunits, including
ANAPC2, are phosphorylated in the cell [75]. Consequently, no
eukaryotic posttranslational modiﬁcation is required, for either
ubiquitin chain elongation or its inhibition by Emi2 ZBR–RL. Thus,
the mCRLA system was shown to include the target of Emi2 ZBR–
RL, and was therefore employed hereafter for the in vitro ubiquitin
polymerization inhibition assay.
Remarkably, the ZBR fragment without the C-terminal tail still
exhibited the inhibitory activity against ubiquitin chain elongation
(Fig. 6D; Supplementary Fig. S5A). In contrast, an Emi1 fragment
corresponding to the ZBR domain without the C-terminal tail, con-
sisting of the PZ region and the RL residues, did not inhibit ubiqui-
tin chain elongation by the mCRLA system (Fig. 6E).
Correspondingly, overexpression of the ZBR fragment of Emi1 did
not impair mitosis under the same conditions (Fig. 3D and E).
The inhibitory activities of the Emi2 ZBR–RL and ZBR fragments
against ubiquitin chain elongation were compared (Fig. 6F and G;
Supplementary Fig. S5A). In comparison with the control, the levels
of poly-ubiquitin chain production were reduced to 28% (78%
reduction) and 58% (42% reduction) in the presence of the ZBR–
RL and ZBR fragments, respectively. The inhibitory activity of the
Emi2 ZBR fragment is increased only by about twofold, by fusion
to the C-terminal tail. Hence, the properties of the ZBR fragments
distinguish Emi2 from Emi1.
We then performed the in vitro ubiquitylation assay using the
mCRLA system for the Emi2 ZBRmutants, K587M and K586M. Note
that these two Lys residues do not have any corresponding resi-
dues in Emi1. While the K586M mutation only slightly reduced
the inhibitory activity against ubiquitin chain elongation, the
K587Mmutation resulted in loss of function (Fig. 6H and I; Supple-
mentary Fig. S5C). The HSQC spectra of the WT and mutant ZBR
fragments displayed well-dispersed peaks characteristic of folded
proteins, indicating that the two mutants are fully folded (Supple-
mentary Fig. S6D). Thus, these residues, especially K587, within the
Emi2 ZBR domain are responsible for the inhibition of the ubiqui-
tylation by the mCRLA. We then examined the ubiquitylationsensitivity of the ZBR domain mutants in cells, by transfecting
the AcGFP-Emi2 ZBR into HEK 293T cells, and found that the
K587M mutant was more easily polyubiquitylated than the WT
and the other mutants (Supplementary Fig. S6A–C). These results
indicated that K587 is crucial for the inhibitory activity of the
Emi2 ZBR domain against ubiquitin chain elongation. On the other
hand, the K586M mutation has the largest inﬂuence on the cell
division abnormalities induced by the ZBR fragment (Fig. 4A and
B), although K586 contributes only slightly to the inhibition of
ubiquitin chain elongation (Fig. 6H and I; Supplementary
Fig. S5C, S6B, C). The side chain of K586 is oriented oppositely, as
compared with that of K587 (Fig. 4E; Supplementary Fig. S6D). Fur-
thermore, the K586M mutation impairs the Cdc20APC/C interac-
tion for both the ZBR and ZBR–RL fragments (Fig. 4C and D), and
thus K586 contributes substantially to prevent Cdc20 re-associa-
tion with the core APC/C (Fig. 4F).
The ubiquitin chain-extending E2, E2S/UBE2S, is an auxiliary
factor for APC/C required for recovery from abnormally stopped
cell proliferation, but not for normal cell-cycle progression [76].
The E2S drives the elongation of K11-linked ubiquitin chains and
enhances protein degradation by branched ubiquitin chains
[77,78]. Recent studies reported that both E2C and E2S are required
for rapid cyclin B degradation and exit from cytostatic arrest upon
fertilization in Xenopus eggs [49]. The C-terminal RL residues of
Emi2 competitively inhibits the binding of ubiquitin chain-extend-
ing E2, E2S/UBE2S to ANAPC10, and the RL residues of Emi1/2 com-
pete with the tail of E2S for APC/C binding [48,49]. On the other
hand, our results revealed that the ZBR–RL fragment of Emi2 inter-
acts with ANAPC2, and clearly showed that the ZBR–RL fragments
of Emi1 and Emi2 are available to inhibit the ubiquitin chain elon-
gation by ANAPC2–11 and E2C (Fig. 5). In addition, E2C interacts
with ANAPC2 [20,73], while E2S interacts with ANAPC10 [49].
Thus, it is possible that the Emi2APC2–11 interaction inhibits
APC2–11E2C-mediated ubiquitylation, whereas the Emi2APC10
interaction inhibits E2S-mediated ubiquitylation. On the other
hand, Emi2 reportedly did not prevent the association of E2C with
APC/C in the ubiquitylation reaction [47]. Moreover, our results
showed that the ZBR–RL and ZBR fragments of Emi2 preferentially
inhibit ubiquitin elongation (Figs. 5 and 6). Therefore, the Emi2 ZBR
domain functions by interfering with the ubiquitin chain assembly
reaction, rather than interrupting E2C binding to ANAPC2.
3.7. The key residues exerting the characteristics of the Emi2 ZBR
domain
The functional residues of the ZBR domains were compared
between Emi1 and Emi2 (Fig. 7A, B, and D). The ZBR residues
K571, Q577, K586, K587, and C606 are highly conserved among
the Emi2 orthologs from vertebrates (Fig. 3C; Supplementary
Fig. S3A). In contrast, with the exception of K571, none of these res-
idues are conserved in Emi1 or important for its function [41].
Thus, it seems that the roles of the ZBR domains are completely dif-
ferent between Emi2 and Emi1. Notably, the ZBR residues Q577,
K586, and K587 (Fig. 7A) are highly conserved among the Emi2
orthologs from vertebrates. These residues are likely to be respon-
sible for the Emi2-speciﬁc ZBR-domain functions. We therefore
transplanted the Emi2-speciﬁc residues into the Emi1 ZBR frag-
ment (Fig. 6C–E). These Emi1 ZBR mutants, except for N356Q (cor-
responding to Q577 of Emi2), gained the ubiquitylation inhibitory
activity against the mCRLA system (Fig. 6E). These results con-
ﬁrmed that Q577 of Emi2 is not involved in the inhibition of ubiq-
uitin chain elongation. Moreover, we examined the effects of these
mutations on the mitotic phenotype of HEK293T cells, by a trans-
fection assay with the expression vector encoding the AcGFP fused
to the Emi1 ZBR-domain fragment. Mutations in the Emi1 ZBR
fragment actually conferred the abnormal Emi2 ZBR-induced mito-
Fig. 7. The key residues exerting the characteristic inhibitory activity of the Emi2 ZBR-domain against APC/C. (A and B) Comparison of the Emi2 and Emi1 ZBRs by surface
mapping of the functional residues involved in the inhibition of the APC/C E3 activity. The images on the top show surface representations of Emi2 ZBR (A) and Emi1 ZBR (B),
in the same orientation. The merged images of the ribbon diagram and the surface structure are displayed at the bottom, respectively. The Emi2 residues colored red-brown
and cyan correspond to the putative Cdc20 separation mechanism illustrated in Fig. 4F. K587 (cobalt blue) is responsible for the inhibition of ubiquitin chain elongation
(Fig. 5H and I; Supplementary Fig. S6). The Emi1 residues colored yellow-orange are related to the inhibition of the ubiquitin chain elongation by the APC/C-Cdh1 with E2C
[41]. (C) Pairwise sequence alignment of the ZBR–RL regions from the mouse (Mm) and human (Hs) Emi/Erp family proteins. The amino acid sequence similarity between
mouse and human: Emi1, 79.2% identical, Emi2, 86.3% identical (GENETYX). Arrows indicate the target residues within the Emi1 ZBR domain for the transplantation of Emi2-
speciﬁc residues: N356Q of Mm Emi1 for Q577 of Mm Emi2; L365K of Mm Emi1 for K586 of Mm Emi2; E366K of Mm Emi1for K587 of Mm Emi2. The star indicates the
functional Lys (K) residue conserved in the Emi1 and Emi2 ZBRs. (D) WB showing the effects of the transplantation of Emi2-speciﬁc residues into the Emi1 ZBR fragment on
the mCRLA-mediated ubiquitin chain elongation. (E) Cellular phenotypes associated with the AcGFP-Emi1 ZBR mutants constructed by the transplantation of the Emi2-
speciﬁc residues. Scale bar, 100 lm. Images of these transfectants stained with Hoechst 33342 for nuclear DNA are shown in Supplementary Fig. S7. (F) The functional
residues of the Emi2 ZBR-domain surface, which are related to the inhibition of the APC/C activity. (G) Schematic representation of the inhibition mechanisms against APC/C-
Cdc20 by the Emi2 ZBR domain and the post-ZBR (PZ) region. The C-terminal tail of Emi2 consists of the PZ region and the RL residues. The PZ region binds to ANAPC2 within
the cullin-RING ligase module of APC/C (ANAPC2–11 subcomplex) while the RL residues bind to ANAPC10. The Emi2 ZBR domain inhibits the ubiquitin chain elongation by
the ANAPC2–11 subcomplex combined with E2C. On the other hand, the Emi2 ZBR domain binds to the coactivator Cdc20 and impairs its association with the APC/C core
complex, thereby turning off the E3 activity. The PZ region enhances the ZBR-mediated activities by anchoring it to the APC/C catalytic core complex. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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L365K > N356QP L365K/E366K >> E366K > L365K (Fig. 7E; Sup-
plementary Fig. S7). We observed the Emi2-like abnormal mitotic
phenotype in the Emi1 ZBR mutants with N356Q. In contrast, the
L365K and E366K mutations hardly inﬂuenced cell division. These
results indicate that the contribution of the APC/C activator separa-
tion to the cell-division inhibiting activity is superior to that of the
ubiquitin elongation inhibition.
Collectively, as shown in Fig. 7F, the putative Cdc20-dissociating
residues of the Emi2 ZBR domain, K571, Q577, and C606, are clus-
tered on one face (designatedhere as the ‘‘front face’’) of the domain.
On the other hand, the K587 residue, required for the inhibition of
ubiquitin chain elongation, is located on the ‘‘side face’’. The K586
residue, on the ‘‘back face’’, is involved in the inhibition of ubiquity-
lation and responsible for preventing the re-association of APC/
CCdc20. Consequently, the ZBR domain of Emi2 exerts the cell-divi-
sion inhibiting activity through a combination of two mechanisms
(Fig. 7G). In one, the ZBR domain binds to the coactivator Cdc20
and impairs its association with the APC/C core complex. In the
other, the ZBR inhibits the ubiquitin chain elongation by the APC/C
cullin-RING ligase (CRL) module, ANAPC2–11 complex, in combina-
tion with the ubiquitin chain initiating E2, E2C. In addition, we
determined the solution structure of the Emi2 ZBR domain, and
the post-ZBR (PZ) region interacts with the CRL module of APC/C.
4. Conclusions
The present ﬁnding of the two novel inhibitory mechanisms
(separation of Cdc20 and inhibition of E2C) for the Emi2 ZBR
domain will provide a solid foundation for future studies on the
functions of Emi2 in in vivo systems, i.e., mammalian oocytes and
early embryos. In particular, we identiﬁed the single mutations
within the Emi2 ZBR domain that selectively impair each of the
two new inhibitory mechanisms, which will be useful for distin-
guishing the multiple inhibitory mechanisms potentially mediated
by Emi2. We hope that our ﬁndings will be shared and utilized
among the scientiﬁc community.
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